首页 Intercept制药(usICPT)-基本信息

Intercept制药(usICPT)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:20.46

最高价:21.5

成交量:5355408.0

昨收价:20.55

最低价:19.82

最新价:20.28

行情图标
概要信息

中文名称:Intercept制药


英文名称:Intercept Pharmaceuticals


简介:Intercept Pharmaceuticals, Inc.于2002年9月4日在特拉华州注册,是一家发展阶段的制药公司,主要集中于利用其专有的胆汁酸化学来针对慢性肝脏疾病的新型治疗法的研发与销售


电话:1-646-7471000


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Intercept Pharmaceuticals, Inc.专注于新型疗法之发现、开发与商业化,利用其专利胆酸化学技术,治疗慢性肝脏及肠道疾病。Intercept Pharmaceuticals公司产品有: Obeticholic Acid (OCA,INT-747)(6-乙基鹅去氧胆酸)——一种胆汁酸类似物,产品已完成原发性胆汁性胆管炎治疗的III期临床试验;处于非酒精性脂肪肝治疗的II期临床阶段;处于酒精性脂肪肝治疗的III期临床试验阶段;处于原发性硬化性胆管炎治疗的II期临床试验阶段;处于胆道闭锁治疗的II期临床试验阶段; INT-767——一种口服给药的双重FXR和TGR5激动剂,目前处于纤维化病治疗的I期临床试验阶段; INT-777——一种口服给药的TGR5激动剂,目前处于2型糖尿病治疗的临床前阶段。Intercept Pharmaceuticals(ICPT)历史百科: 2012年10月16日,Intercept Pharmaceuticals, Inc. IPO登陆纳斯达克,发行价15美金; 2013年6月24日,以33美金/股增发; 2014年1月9日,ICPT股价暴涨280+%,从$72.39到$275.49,接下来的几天更是爬到了$497一股,因为独立数据安全监测委员会分析后发现Obeticholic Acid在中间阶段达到主要目标。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-12 Kim (Richard J) Officer Sell 111 69.71
2019-07-02 Bright (Lisa) Officer Sell 595 78.66
2019-06-30 Pruzanski (Mark) Chief Executive Officer Sell 1548 79.17
2019-06-30 Durso (Jerome Benedict) Chief Operating Officer Sell 289 79.17
2019-06-30 Bright (Lisa) Officer Sell 530 79.17
2019-06-30 Ford (David A) Officer Sell 92 79.17
2019-06-30 Kapadia (Sandip S.) Chief Financial Officer Sell 615 79.17
2019-06-30 Kim (Richard J) Officer Sell 268 79.17
2019-06-30 Weyer (Christian) Officer Sell 46 79.17
2019-06-19 Gottesdiener (Keith Michael) Director Buy 1570 --
2019-06-19 Santini (Gino) Director Buy 1570 --
2019-06-19 Fundaro (Paolo) Director Buy 1570 --
2019-06-19 Akkaraju (Srinivas) Director Buy 1570 --
2019-06-19 Sblendorio (Glenn P) Director Buy 1570 --
2019-06-19 Bradbury (Daniel M) Director Buy 1570 --
2019-06-19 Welch (Daniel G) Director Buy 1570 --
2019-06-19 Benatti (Luca) Director Buy 1570 --
2019-06-19 Miller-Rich (Nancy) Director Buy 1570 --
2019-05-26 Weyer (Christian) Officer Sell 357 87.83
2019-05-22 Durso (Jerome Benedict) Chief Operating Officer Sell 460 85.51
2019-05-19 Fundaro (Paolo) Director Buy 3461 9.30
2019-05-19 Fundaro (Paolo) Director Buy 3288 21.50
2019-05-13 Benatti (Luca) Director Buy 1200 83.50
2019-05-13 Akkaraju (Srinivas) Director Buy 119760 83.50
2019-05-12 Sullivan Ryan T General Counsel Sell 711 83.73

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Northern Trust Investments Inc 440675 1.35% 17718 4.19% 2019-07-31
State Street Corporation 1120714 3.44% 193417 20.86% 2019-03-31
BlackRock Fund Advisors 1428504 4.39% 10700 0.75% 2019-07-31
Fidelity SelectCo, LLC 1488000 4.57% -- -- 2019-07-31
BlackRock Inc 1954871 6.01% -77416 -3.81% 2019-03-31
Vanguard Group Inc 2041948 6.27% 35326 1.76% 2019-03-31
Fidelity Management & Research Company 3180772 9.77% -112866 -3.43% 2019-07-31
Fidelity Management and Research Company 4181426 12.85% 10199 0.24% 2019-03-31
FMR Inc 4453270 13.68% 5100 0.11% 2019-03-31
First Trust Advisors L.P. 901976 2.77% -79507 -8.10% 2019-03-31
J.P. Morgan Investment Management, Inc. 771132 2.37% 15885 2.10% 2019-07-31
Bellevue Asset Management AG 721724 2.22% -7400 -1.01% 2019-07-31
Adage Capital Partners Gp LLC 505000 1.55% 367000 265.94% 2019-03-31
Point72 Asset Management, L.P. 648278 1.99% 568078 708.33% 2019-03-31
SENVEST INTERNATIONAL LLC 662200 2.03% 662200 -- 2019-03-31
RIMA MANAGEMENT, LLC 662200 2.03% 662200 -- 2019-03-31
Citadel Advisors Llc 674348 2.07% 529313 364.96% 2019-03-31
BB Biotech AG 696976 2.14% 121257 21.06% 2019-03-31
Vanguard Investments Australia Ltd 699576 2.15% 327170 87.85% 2019-07-31
SSGA Funds Management Inc 716728 2.20% -9570 -1.32% 2019-07-31
Goldman Sachs Group Inc 433113 1.33% 115500 36.37% 2019-03-31
Franklin Resources Inc 428500 1.32% 145200 51.25% 2019-03-31
Geode Capital Management, LLC 519772 1.60% 281945 118.55% 2018-12-31
BlackRock Asset Management Canada Ltd 499617 1.54% 24405 5.14% 2019-05-31
Deutsche Asset Management Investment GmbH 325473 1.09% 9022 2.85% 2019-04-30
Two Sigma Investments LLC 310187 1.04% 86771 38.84% 2018-12-31
Deutsche Bank AG 369619 1.24% -69101 -15.75% 2018-12-31
Boxer Capital LLC 600000 2.01% 600000 -- 2018-12-31
JPMorgan Chase & Co 1197042 4.03% -75239 -5.91% 2018-09-30
Marshall Wace North America LP 396610 1.34% 367911 1281.96% 2018-09-30
Deutsche Asset Mgmt Invst Gesenschaft 297998 1.00% 81009 37.33% 2018-12-31
Altrinsic Global Advisors LLC 277944 0.94% -34683 -11.09% 2018-12-31
Northern Trust Corp 267381 0.90% 9626 3.73% 2018-09-30
Franklin Advisers, Inc. 283300 0.96% 162200 133.94% 2019-01-31
Northern Trust Investments N A 267381 0.90% 9626 3.73% 2018-09-30
Fidelity Institutional Asset Management 258243 0.87% -13800 -5.07% 2018-09-30
Highfields Capital Management LP 339232 1.14% -- -- 2018-06-30
BlackRock Institutional Trust Company NA 581497 1.96% 86860 17.56% 2018-06-30
Sarissa Capital Management LP 635300 2.14% -- -- 2018-06-30
Capital Research and Management Company 1228337 4.14% -706622 -36.52% 2018-11-30
Genextra SpA 6845578 23.26% 390625 6.05% 2018-04-09
State Street Corp 1328409 4.49% -68646 -4.91% 2018-06-30
J.P. Morgan Investment Management Inc 923488 3.12% -268947 -22.55% 2018-06-30
J P Morgan Asset Management (UK) Ltd 255833 0.87% -72227 -22.02% 2018-06-30
Elk Creek Partners LLC 386397 1.31% 37943 10.89% 2018-06-30
Deutsche Asset & Wealth Management Investment GmbH 214673 0.71% -17 -0.01% 2018-09-06
Capital World Investors 1244759 4.91% 81000 6.96% 2018-03-31
Millennium Management LLC 235180 0.93% 147719 168.90% 2018-03-31
Pinnacle Associates Inc 206430 0.81% -8860 -4.12% 2018-03-31
UBS Securities LLC 206300 0.81% 15675 8.22% 2018-03-31
OZ Management LLC 182700 0.73% -- -- 2017-12-31
Morgan Stanley & Co Inc 416461 1.65% 205975 97.86% 2017-12-31
Jackson National Asset Management LLC 182500 0.72% 64213 54.29% 2017-12-31
Carmignac Gestion Luxembourg 159577 0.64% 8600 5.70% 2017-06-30
Jefferies & Company Inc 258759 1.03% 256831 13321.11% 2017-09-30
Orbimed Advisors, LLC 386380 1.54% -470174 -54.89% 2017-09-30
Columbia Mangmt Investment Advisers, LLC 1185405 4.72% -1322495 -52.73% 2017-10-31
J.P. Morgan Investment Management Inc. 2007198 8.00% 2007198 -- 2017-12-29
Managed Account Advisors LLC 246336 0.98% 4379 1.81% 2017-09-30
Credit Suisse First Boston (CSFB) 192183 0.77% 44578 30.20% 2017-09-30
Delaware Management Business Trust 237431 0.95% -4134 -1.71% 2017-06-30
Columbia Management Investment Advisers LLC 226518 0.91% -- -- 2016-12-31
Columbia Wanger Asset Management LLC 192510 0.78% -41063 -17.58% 2016-09-30
Carmignac Gestion 2015192 8.13% 21600 1.08% 2016-09-30
FMR LLC 3203951 10.00% 582798687 0.10% 1999-11-30
Genextra S.p.A. 6454953 10.00% 1174155951 0.30% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
iShares Russell 2000 ETF 547504 1.68% 7903 1.46% 2019-07-30
First Trust NYSE Arca Biotech Fund 1369380 4.21% -3300 -0.24% 2019-07-31
SPDR 710261 2.18% 13927 2.00% 2019-07-31
Vanguard Total Stock Market Index Fund 694076 2.13% 327202 89.19% 2019-06-30
Vanguard Small Cap Index 670880 2.06% -2258 -0.34% 2019-06-30
Vanguard Small Cap Growth Index Fund 382558 1.18% 1341 0.35% 2019-06-30
Vanguard Extended Market Index Fund 329843 1.01% -1825 -0.55% 2019-06-30
iShares Nasdaq Biotechnology ETF 322374 0.99% 2838 0.89% 2019-07-30
Franklin Biotechnology Discovery Fund 254200 0.78% -- -- 2019-06-30
JPMorgan Small Cap Growth Fund 233380 0.72% 6936 3.06% 2019-06-30
iShares Russell 2000 Growth ETF 227382 0.70% 4084 1.83% 2019-07-30
Fidelity 217698 0.67% 23400 12.04% 2019-04-30
Vanguard Small Cap Index Fund 580855 1.78% 4150 0.72% 2019-04-30
DWS Verm 200000 0.61% -- -- 2019-03-31
iShares US Small Cap ETF (CAD-Hedged) 446506 1.37% -747 -0.17% 2019-05-30
American Funds SMALLCAP World Fund 213137 0.65% -- -- 2019-03-31
Fidelity Advisor 201905 0.62% -- -- 2019-04-30
Carillon Eagle Small Cap Growth Fund 202771 0.68% 202771 -- 2018-12-31
JPMorgan Growth Advantage Fund 317600 1.07% -72400 -18.56% 2019-01-31
VA CollegeAmerica SMALLCAP Wld Fd 213137 0.72% -- -- 2018-12-31
iShares Exponential Technologies ETF 198933 0.67% -- -- 2018-11-30
American Funds IS 325000 1.10% -- -- 2018-03-31
Delaware Smid Cap Growth Fund 244175 0.82% -27675 -10.18% 2017-08-31
American Funds Growth Fund of Amer 690200 2.33% -- -- 2017-09-30
VA CollegeAmerica Amer Blcd Fd 706622 2.38% -- -- 2018-03-31
American Funds American Balanced Fund 706622 2.38% -- -- 2018-03-31
JPMorgan Mid Cap Growth Sel 184271 0.62% -38800 -17.39% 2018-07-31
First Trust NYSE Arca Biotech ETF 791716 2.83% -- -- 2018-09-13
Vanguard Total Stock Mkt Idx 555172 1.88% 672 0.12% 2018-07-31
iShares Nasdaq Biotechnology 335660 1.19% -639 -0.19% 2018-09-12
Vanguard Small Cap Growth Index Inv 319008 1.08% 5443 1.74% 2018-07-31
JPMorgan Growth Advantage A 383600 1.30% 2700 0.71% 2018-07-31
Vanguard Extended Market Idx Inv 275688 0.93% 2300 0.84% 2018-07-31
iShares Russell 2000 Growth 210693 0.74% -203 -0.10% 2018-09-12
iShares Exponential Technologies 194786 0.69% -- -- 2018-09-12
VA CollegeAmerica Smcap World 529E 213137 0.72% -- -- 2018-06-30
American Funds NVIT Growth II 325000 1.28% -- -- 2018-03-31
VA CollegeAmerica Amercn Bal 529E 706622 2.79% -- -- 2018-03-31
JNL/JPMorgan Mid Cap Growth B 182500 0.72% 67400 58.56% 2017-12-31
VA CollegeAmerica Grth Fund of Amer 529F 690200 2.75% -- -- 2017-09-30
Active Portfolios 226518 0.91% -- -- 2016-12-31
Columbia Select Large Cap Growth Z 1033894 4.17% -69591 -6.31% 2016-12-31
Columbia Select Large Cap Growth Fund 827863 3.40% 78430 10.50% 2015-09-30
Hansard EU Carmignac Patrimoine 812089 3.60% -56204 -6.50% 2015-03-31
VA CollegeAmerica Growth Fund of America 652400 2.70% 152400 30.50% 2015-09-30
Hansard EU Carmignac Investissement 479611 2.10% -26959 -5.30% 2015-03-31
Fidelity® OTC Portfolio 315719 1.30% 1100 0.40% 2015-10-31
American Funds NVIT Growth 306200 1.30% 76200 33.10% 2015-09-30
Fidelity® Select Health Care Portfolio 256900 1.10% 700 0.30% 2015-10-31
Fidelity® Independence Fund 201600 0.80% -- -- 2015-10-31
Active Portfolios® Multi-Manager Gr Fd 182812 0.80% 17410 10.50% 2015-09-30
Fidelity® Select Biotechnology Portfolio 1193868 4.90% -- -- 2015-10-31

Srinivas Akkaraju Dr. Srinivas Akkaraju is an Independent Director at Syros Pharmaceuticals, Inc., a Principal at Samsara Biocapital, LLC, an Independent Director at ZS Pharma, Inc., an Independent Director at Intercept Pharmaceuticals, Inc., an Independent Director at Seattle Genetics, Inc. and a Chairman at Aravive, Inc. He is on the Board of Directors at Syros Pharmaceuticals, Inc., ZS Pharma, Inc., Intercept Pharmaceuticals, Inc., Seattle Genetics, Inc., A2 Biotherapeutics, Inc., Mirobio Ltd. and The George Institute for Global Health. Dr. Akkaraju was previously employed as an Independent Director by aTyr Pharma, Inc., a Chairman by Versartis, Inc., a Managing General Partner by Sofinnova Ventures, Inc., a Managing Director by New Leaf Venture Partners LLC, an Independent Director by Pharmos Corp., a Managing Director by Panorama Capital LLC, a Partner by J.P. Morgan Partners LLC, a Senior Manager by Genentech, Inc., a Member by BioStreet, Inc., and an Independent Director by Principia Biopharma, Inc. He also served on the board at Amarin Corp. Plc, Phenomix Corp., Barrier Therapeutics, Inc., Eyetech Pharmaceuticals, Inc., Itero Biopharmaceuticals, Inc., Pharmos, Inc., Piramed Ltd., Presidio Pharmaceuticals, Inc., Synageva BioPharma Corp. and Synageva BioPharma Corp. /Old/. He received his undergraduate degree from Rice University and a doctorate degree from Stanford University School of Medicine.
Gino Santini Currently, Gino Santini is Chairman for AMAG Pharmaceuticals, Inc. He is also on the board of 8 other companies. In his past career he was Senior VP-Business Development & Strategy at Eli Lilly & Co. and General Manager for Eli Lilly y CIA de M�0�1�0�8xico SA de CV (a subsidiary of Eli Lilly & Co.), Chairman at National Pharmaceutical Council and Chairman for Noble of Indiana. Gino Santini received an undergraduate degree from the University of Bologna and an MBA from the University of Rochester Simon Business School.
Daniel Mark Bradbury Founder of Equillium, Inc. and Sensulin LLC, Daniel Mark Bradbury is an American businessperson who has been the head of 9 different companies and is Chairman at Castle Biosciences, Inc., Chairman at Liquidgrids, Inc., Chairman for Thesan Pharmaceuticals, Inc., Chairman & Chief Executive Officer at Equillium, Inc., Chairman of Freedom Meditech, Inc., Chairman for Neurovia, Inc., Co-Chairman of Sensulin LLC and Chairman for ADCY5 Org. Daniel Mark Bradbury is also Managing Member at BioBrit LLC and Member of Royal Pharmaceutical Society of Great Britain and on the board of 13 other companies. He previously occupied the position of President, Chief Executive Officer & Director at Amylin Pharmaceuticals, Inc. and Principal at Smithkline Beecham Pharmaceuticals (India) Ltd. Mr. Bradbury received an undergraduate degree from The University of Nottingham.
Glenn P. Sblendorio Glenn P. Sblendorio holds the position of President, Chief Executive Officer & Director at IVERIC bio, Inc. Mr. Sblendorio is also on the board of Amicus Therapeutics, Inc. and Intercept Pharmaceuticals, Inc. Mr. Sblendorio previously held the position of Chairman for NuLens Ltd., Chief Executive Officer & Managing Director at Mpm Capital Advisors LLC, President, CFO, Treasurer & Director at The Medicines Co., Chief Financial Officer at Millennium Venture Management LLC, Head-Finance & Controller at Amgen, Inc., Chief Financial Officer & Executive Vice President for Eyetech Pharmaceuticals, Inc., Chief Financial Officer of Hoffmann-La Roche, Inc., Chief Financial Officer & Vice President-Finance of Roche Molecular Systems, Inc. and Managing Director at Sony Interactive Entertainment, Inc. Glenn P. Sblendorio received an MBA from Fairleigh Dickinson University and an undergraduate degree from Pace University.
Daniel G. Welch Mr. Daniel G. Welch is Executive Partner at Sofinnova Ventures, Inc., Independent Director at Hyperion Therapeutics, Inc., and Independent Director at Seattle Genetics, Inc. He has over 30 years of experience across both multi-national pharmaceutical companies and biotech companies. Mr. Welch joined Sofinnova Ventures in 2015. Most recently, he was the Chairman, CEO and President of InterMune. Beginning in 2003, he led a comprehensive company turn-around, refocusing the company's development efforts. He built the InterMune development and commercial teams that delivered the successful approval of Esbriet. In October 2014, Roche acquired InterMune. From August 2002 to January 2003, he served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., a pharmaceutical company. From October 2000 to June 2002, he served as president of the pharmaceutical division of Elan Corporation, PLC (acquired by Perrigo). From September 1987 to August 2000, he served in various senior management roles at Sanofi-Synthelabo (now Sanofi) and its predecessor companies Sanofi and Sterling Winthrop. During his time at Sanofi, he led the successful worldwide launches of Plavix, Eloxatin and Avapro as Vice President of Worldwide Marketing and he served as COO of the U.S. business. From November 1980 to September 1987, he was with American Critical Care, a division of American Hospital Supply. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina.
Glenn P. Sblendorio Glenn P. Sblendorio holds the position of President, Chief Executive Officer & Director at IVERIC bio, Inc. Mr. Sblendorio is also on the board of Amicus Therapeutics, Inc. and Intercept Pharmaceuticals, Inc. Mr. Sblendorio previously held the position of Chairman for NuLens Ltd., Chief Executive Officer & Managing Director at Mpm Capital Advisors LLC, President, CFO, Treasurer & Director at The Medicines Co., Chief Financial Officer at Millennium Venture Management LLC, Head-Finance & Controller at Amgen, Inc., Chief Financial Officer & Executive Vice President for Eyetech Pharmaceuticals, Inc., Chief Financial Officer of Hoffmann-La Roche, Inc., Chief Financial Officer & Vice President-Finance of Roche Molecular Systems, Inc. and Managing Director at Sony Interactive Entertainment, Inc. Glenn P. Sblendorio received an MBA from Fairleigh Dickinson University and an undergraduate degree from Pace University.
Luca Benatti Founder of Newron Pharmaceuticals SpA, Luca Benatti currently holds the position of Chairman of Italian Angels For Biotech and Chief Executive Officer & Director at EryDel SpA. He is also on the board of Intercept Pharmaceuticals, Inc., Newron Pharmaceuticals SpA (former CEO, Executive Director, MD & Head-Media Relations) and Assobiotec and Principal at The European Association for Bioindustries. In the past Dr. Benatti held the position of Head-Molecular Neurobiology Department at Pharmacia & Upjohn SpA. Dr. Benatti received an undergraduate degree from the University of Milan.
David A. Shapiro Founder of Integrated Quality Resources, Inc., David A. Shapiro presently is Chief Medical Officer of Intercept Pharmaceuticals, Inc. Dr. Shapiro is also on the board of Organovo Holdings, Inc. and Member of The Royal College of Physicians. In his past career Dr. Shapiro was President for Scripps Clinic Medical Group, Inc., Chief Medical Officer & EVP-Medical Affairs at Idun Pharmaceuticals, Inc., Principal at Merck Sharp & Dohme Ltd., Vice President-Clinical Research at Gensia Pharmaceuticals, Inc. and Trustee & Vice President at American Academy of Pharmaceutical Physicians. David A. Shapiro received a doctorate from the University of Dundee School of Medicine.
Ryan T. Sullivan Currently, Ryan T. Sullivan is Secretary & General Counsel at Intercept Pharmaceuticals, Inc., Chief Technology Officer of ANGI Homeservices, Inc. and Executive Vice President-Technology at HomeAdvisor, Inc. He previously held the position of Manager-Content Development at Janus Capital Group, Inc., Executive Vice President & General Counsel at Anacor Pharmaceuticals, Inc. and Secretary, Vice President & General Counsel for Warner Chilcott Plc. Mr. Sullivan received an undergraduate degree from Cornell University and a graduate degree from Cornell Law School.
Mark E. Pruzanski Founder of Intercept Pharmaceuticals, Inc., Apple Tree Partners and Kirax Corp., Mark E. Pruzanski currently holds the position of President, Chief Executive Officer & Director at Intercept Pharmaceuticals, Inc. He is also on the board of Biotechnology Innovation Organization, Foundation for the Defense of Democracies and Equillium, Inc. In the past Dr. Pruzanski was Chief Executive Officer at MedicinePlanet, Inc., Director at gIcare Pharma, Inc., Venture Partner at Apple Tree Partners and Entrepreneur-in-Residence at Oak Investment Partners. Mark E. Pruzanski received a doctorate from McMaster University, an undergraduate degree from McGill University and a graduate degree from Paul H. Nitze School of Advanced International Studies (IT).
Paolo Fundar�0�1�0�5 Paolo Fundar�0�1�0�5 occupies the position of Chairman at Intercept Pharmaceuticals, Inc. and investment Director and Chief Financial Officer at Genextra SpA. He is also on the board of EryDel SpA, Applango USA, Inc., Applango Systems Ltd. and InnovHeart Srl. In his past career he occupied the position of Managing Director & Director at Tethis SpA, Managing Director at Congenia Srl, Managing Director at Dac SRL, Director-Finance & Strategic Planning at Fastweb SpA, Principal at Salomon Smith Barney International Ltd. and Principal at Credit Suisse (USA), Inc. Mr. Fundar�0�1�0�5 received an undergraduate degree from the University of Bocconi.
Christian Weyer Presently, Christian Weyer holds the position of Executive Vice President-Research & Development at Intercept Pharmaceuticals, Inc. In the past Dr. Weyer held the position of President, Chief Executive Officer & Director at Fate Therapeutics, Inc., President & Chief Development Officer at Profil Institute for Clinical Research, Inc., Senior Vice President-Research & Development at Amylin Pharmaceuticals, Inc. and Director-Accounting, Sales & Marketing at EKF-diagnostic GmbH. Dr. Weyer received a graduate degree from the University of California San Diego and a doctorate from Heinrich-Heine-Universit�0�1¤t D�0�1�0�4sseldorf.
Keith M. Gottesdiener Keith M. Gottesdiener is President, Chief Executive Officer & Director at Rhythm Pharmaceuticals, Inc. Dr. Gottesdiener is also on the board of Intercept Pharmaceuticals, Inc. In the past he was Chairman & Chief Executive Officer for Allergan GI Corp., Vice President of Merck Research Laboratories, Head-Late Development at Schering-Plough Corp. and Associate Clinical Professor-Medicine at Columbia University. Dr. Gottesdiener received a doctorate from the University of Pennsylvania and an undergraduate degree from Harvard College.
Mark J. Vignola Presently, Mark J. Vignola occupies the position of Director-Investor Relations of Intercept Pharmaceuticals, Inc. In the past Dr. Vignola held the position of Analyst at Lehman Brothers, Inc., Equity Research Associate at Needham & Co. LLC and Research Assistant at Duke University Medical Center. Mark J. Vignola received a doctorate and a graduate degree from Duke University and an undergraduate degree from Boston College.
Lisa Bright Lisa Bright is on the board of Dechra Pharmaceuticals Plc and Ascendis Pharma An and President-International at Intercept Pharmaceuticals, Inc. In the past Ms. Bright occupied the position of Vice President at GlaxoSmithKline Plc, General Manager of Gilead Sciences Ireland UC and General Manager for Gilead Sciences Ltd. Lisa Bright received an undergraduate degree from University College London.
David Ford David Ford holds the position of Director-Human Resources of Sanofi-Synthelabo Ireland Ltd. and Chief Human Resources Officer at Intercept Pharmaceuticals, Inc. Mr. Ford is also on the board of Lightpoint Medical Ltd. In the past Mr. Ford held the position of Vice President-Human Resources for Sanofi Genzyme, Vice President-Human Resources at Sanofi US Services, Inc. and Director-Human Resources for Sanofi-Synth�0�1�0�8labo Ltd. Mr. Ford received an MBA from INSEAD.
Daniel G. Welch Mr. Daniel G. Welch is Executive Partner at Sofinnova Ventures, Inc., Independent Director at Hyperion Therapeutics, Inc., and Independent Director at Seattle Genetics, Inc. He has over 30 years of experience across both multi-national pharmaceutical companies and biotech companies. Mr. Welch joined Sofinnova Ventures in 2015. Most recently, he was the Chairman, CEO and President of InterMune. Beginning in 2003, he led a comprehensive company turn-around, refocusing the company's development efforts. He built the InterMune development and commercial teams that delivered the successful approval of Esbriet. In October 2014, Roche acquired InterMune. From August 2002 to January 2003, he served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., a pharmaceutical company. From October 2000 to June 2002, he served as president of the pharmaceutical division of Elan Corporation, PLC (acquired by Perrigo). From September 1987 to August 2000, he served in various senior management roles at Sanofi-Synthelabo (now Sanofi) and its predecessor companies Sanofi and Sterling Winthrop. During his time at Sanofi, he led the successful worldwide launches of Plavix, Eloxatin and Avapro as Vice President of Worldwide Marketing and he served as COO of the U.S. business. From November 1980 to September 1987, he was with American Critical Care, a division of American Hospital Supply. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina.
Richard Kim Richard Kim is President-U.S. Commercial & Strategic Marketing at Intercept Pharmaceuticals, Inc.
Nancy Miller-Rich Presently, Nancy Miller-Rich is Executive Chairman at Altum Pharmaceuticals, Inc. She is also on the board of Global Alliance for TB Drug Development, Intercept Pharmaceuticals, Inc. and UDG Healthcare Plc. In her past career she held the position of Senior Vice President-Business Development at Merck & Co., Inc. and SVP-Global Human Health Business Development at Schering-Plough Corp. (a subsidiary of Merck & Co., Inc.). She received an undergraduate degree from Ithaca College.
Sandip S. Kapadia Presently, Sandip S. Kapadia is Chief Financial Officer & Treasurer of Intercept Pharmaceuticals, Inc. Mr. Kapadia is also on the board of Therachon Holding AG. In the past Mr. Kapadia held the position of Chief Financial Officer & Vice President of Novartis Pharmaceuticals BV, Chief Financial Officer & Vice President of Novartis Pharmaceuticals UK Ltd., Head-Finance of Novartis Pharmaceuticals AG, Head-Finance of Novartis Pharmaceuticals Corp. and VP & Chief Financial Officer-North America at Sandoz, Inc. He received an undergraduate degree from Montclair State University and an MBA from Rutgers Business School.
Jerome B. Durso Jerome B. Durso holds the position of Chief Operating Officer at Intercept Pharmaceuticals, Inc. Mr. Durso is also Chief Commercial Officer & Senior Vice President at Sanofi-Aventis U.S. LLC. He previously occupied the position of Chief Commercial Officer at Sanofi Pharmaceuticals. Mr. Durso received an undergraduate degree from the University of Notre Dame.
Bryan Yoon Mr. Bryan Yoon is a Secretary & General Counsel at Nightstar Therapeutics PLC and a Secretary at Intercept Pharmaceuticals, Inc. He received his undergraduate degree from Cornell University, a graduate degree from The University of Michigan Law School and a graduate degree from Cornell University.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐